viewCreso Pharma Ltd

Creso Pharma welcomes TGA reclassification of CBD for Australian markets

The decision to down schedule cannabidiol products to schedule 3 medicine would allow Australian consumers to purchase CBD products following consultation with a pharmacist without the need for a prescription.

Creso Pharma Ltd - Creso Pharma welcomes the TGA’s reclassification of CBD
The Australian market for CBD and hemp products is estimated to be worth upwards of A$200 million

Creso Pharma Ltd (ASX:CPH) is pleased with the Therapeutic Goods Administration’s (TGA) interim decision regarding a change to the status of cannabidiol (CBD) products in Australia, which could allow the company unprecedented access to the market.

The interim decision recommends that CBD products be down scheduled from schedule 4 and classified as schedule 3 medicines in Australia.

This would allow Australian consumers to purchase CBD products over-the-counter (OTC) through pharmacies without the requirement of a prescription.

"Exciting development"

Creso non-executive director and head of technology, innovation and distribution Miri Halperin Wernli said: “The down scheduling of CBD products in Australia is an exciting development and provides Creso Pharma with a number of key near term opportunities.”

The decision will follow a consultation period with a final decision to be reached by February 1, 2021.

Unlocking market opportunity

This development unlocks a major opportunity for Creso Pharma’s CBD and hemp products and the company will look to progress a number of opportunities to capitalise on a market which is estimated to be valued at A$200 million and set to grow rapidly in the near term.

Halperin Wernli said: “We anticipate that the Australian market will play an important role in the company’s growth trajectory and will grow significantly as CBD becomes more accepted and entrenched with consumers.

“Creso Pharma has a large GMP product range and we are confident that the company’s offering would be well received in Australia.”

Currently, the company’s cannaQIX 50 is being sold in Australia as a medicinal cannabis product under the LozaCan brand via distribution partner Burleigh Heads Cannabis (BHC).

User-friendly formula

Creso Pharma has developed various cannabidiol (CBD) hemp oil-based products in the cannaQIX® range using the company’s proprietary innovative delivery technology.

The products contain broad-spectrum organic hemp oil extracts with CBD and aim at reducing stress and supporting mental and nervous functions.

This range of products is sugar-free and contains no tetrahydrocannabinol (THC).

The standardised, user-friendly strength and formulation allows precise dosage control and the lozenges have a more palatable taste compared to oils.

In addition, the cannaQIX range has been developed to good manufacturing practice standards and is produced in Switzerland by Creso Pharma’s partner, Swiss-based food and pharma development company, Domaco, Dr. med. Aufdermaur AG with a ‘Swiss Made’ label.

Quick facts: Creso Pharma Ltd


Price: 0.12 AUD

Market Cap: $144.19 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


Creso Pharma subsidiary Mernova granted sales license from Health Canada

Creso Pharma (ASX:CPH) subsidiary Mernova managing director Jack Yu and vice president Isaac Allen joined Steve Darling from Proactive to discuss the granting of their sales license from Health Canada and what it allows them to do. Isaac Allen tells Proactive they are gearing up sales efforts...

on 12/6/20

2 min read